| Document |
Document Title |
|
WO/2007/105094 |
Disclosed is a method for producing new leads for drug candidates. The method employs a combinatorial approach for identifying high affinity ligands. The target may be unknown and/or may include one or more unknown binding sites. A metho...
|
|
WO/2007/102396 |
Disclosed is a method for production of a labeled sphingolipid, comprising reacting a sphingolipid or lysosphingolipid with an aliphatic carboxylic acid having a label selected from the group consisting of a substance capable of forming ...
|
|
WO/2007/099557 |
A process for controlling the emission of gaseous by-products in the preparation of a Vilsmeier reagent, and its use as a chlorinating reagent in the production of high intensity sweeteners, such as trichlorogalactosucrose, from partiall...
|
|
WO/2007/100080 |
[PROBLEMS] To provide a method by which the benzyl position in an -O-benzyl group formed by introducing benzyl, benzyloxymethyl, or the like as a hydroxy-protecting group is efficiently and industrially deuterized. [MEANS FOR SOLVING PRO...
|
|
WO/2007/099999 |
It is intended to provide a compound represented by the following general formula (1) or its salt: (1) wherein each symbol is as defined in the description. The above-described compound or its salt can preferentially induce the productio...
|
|
WO/2007/099981 |
To provide a novel and useful galactose derivative, which is a component of a drug carrier enabling the improvement in the liver-targeting properties and the efficient achievement of drug efficacy, a drug carrier containing this derivati...
|
|
WO/2007/099557 |
A process for controlling the emission of gaseous by-products in the preparation of a Vilsmeier reagent, and its use as a chlorinating reagent in the production of high intensity sweeteners, such as trichlorogalactosucrose, from partiall...
|
|
WO/2007/098124 |
This invention describes processes for the convergent synthesis of calicheamicin derivatives of Formula (I)1 and similar analogs using bifunctional and trifunctional linker intermediates.
|
|
WO/2007/096367 |
A process of forming a polyol includes the steps of providing an alkylene oxide, providing an initiator composition having an average functionality of at least four, and providing an alkaline earth metal hydroxide and an amine. The proce...
|
|
WO/2007/096367 |
A process of forming a polyol includes the steps of providing an alkylene oxide, providing an initiator composition having an average functionality of at least four, and providing an alkaline earth metal hydroxide and an amine. The proce...
|
|
WO/2007/096317 |
A process of forming a polyol includes the steps of p roviding an alkylene oxide, providing an initiator composition having an average functionality of at least four, and providing an alkaline earth metal hydroxide and an amine. The proc...
|
|
WO/2007/098124 |
This invention describes processes for the convergent synthesis of calicheamicin derivatives of Formula (I)1 and similar analogs using bifunctional and trifunctional linker intermediates.
|
|
WO/2007/097643 |
This invention relates to compounds that are analogues of coformycin, pharmaceutical compositions containing the compounds, and methods of using the compounds for treating protozoan parasite infections, especially malaria.
|
|
WO/2007/091040 |
A process for the preparation of a thiosaccharide represented by Saccharide-S-H wherein Saccharide comprises at least 4 sugar units, comprises subjecting a corresponding compound of the formula (P)Saccharide-S-(P) wherein (P) represents ...
|
|
WO/2007/091040 |
A process for the preparation of a thiosaccharide represented by Saccharide-S-H wherein Saccharide comprises at least 4 sugar units, comprises subjecting a corresponding compound of the formula (P)Saccharide-S-(P) wherein (P) represents ...
|
|
WO/2007/091393 |
[PROBLEMS] To provide a compound which has a novel structure and is effective against an influenza bacterium and an erythromycin-resistant bacterium (e.g., an erythromycin-resistant pneumococcal or streptococcal bacterium), as well as a ...
|
|
WO/2007/085962 |
This invention relates to compositions and methods of preparing stable adjuvant diluent stock solutions and final adjuvant solutions comprising glycolipids, weak acids, alcohols, nonionic surfactants and buffers.
|
|
WO/2007/085962 |
This invention relates to compositions and methods of preparing stable adjuvant diluent stock solutions and final adjuvant solutions comprising glycolipids, weak acids, alcohols, nonionic surfactants and buffers.
|
|
WO/2007/086884 |
The invention describes novel organic nitric oxide donor salts of a antimicrobial . compounds, and novel compositions and kits comprising at least one organic nitric oxide donor salt of an antimicrobial compound, and, optionally, at leas...
|
|
WO/2007/083594 |
It is intended to provide a laxative with a gentle cathartic action and reduced diarrhea episodes and a food containing the same. A laxative containing genkwanin 5-O-β-primeveroside as an active ingredient. A laxative containing iriflop...
|
|
WO/2007/084856 |
This invention relates to improved methods for purifying polysaccharides from cellular components, such as a cell wall. The method relates to hydrolyzing and separating the polysaccharides, thereby resulting in purified polysaccharides u...
|
|
WO/2007/077770 |
The object is to provide a 4-alkylresorcinol derivative in which defects inherent to a 4-alkylresorcinol are overcome and which is excellent in solubility in water and stability, has substantially no taste and no odor, is not irritative,...
|
|
WO/2007/076704 |
Aryl dihydro-naphthalene lignan derivatives of the following formula with Akt inhibiting activity, and the method of the said compounds and the pharmaceutical composition containing the compounds for treating cancer by inhibiting Akt act...
|
|
WO/2007/075094 |
The present invention relates to novel derivatives of epirubicin, pharmaceutical composition comprising these derivatives, and uses of epirubicin and its derivative for treating HCV.
|
|
WO/2007/076345 |
A method of preparing an anthracyclin such as epirubicin from a starting material comprising 13-dihydrodaunorubicine (13-daunorubicinol). The method comprises producing N-Trifluoroacetyl-13-daunorubicinol from 13-daunorubicinol by acylat...
|
|
WO/2007/075876 |
A process is provided for the preparation of a key intermediate in the preparation of 2'-branched nucleoside compounds. The process includes contacting a protected precursor 3,4-O-isopropylidene-2-C-substituted-D-arabinono-l,5-lactone
w...
|
|
WO/2007/075092 |
New derivatives of 7-O-(3'amino-2',3',6'-trideoxy-α,β,L- arabinoheksopiranosyl)-adriamycinone (epirubicin) presented at Formula 1, where R1, R2, R3 and R4 are the same and indicate hydrogen atom, alkyl group, isopropyl, alkenyl or alki...
|
|
WO/2007/076345 |
A method of preparing an anthracyclin such as epirubicin from a starting material comprising 13-dihydrodaunorubicine (13-daunorubicinol). The method comprises producing N-Trifluoroacetyl-13-daunorubicinol from 13-daunorubicinol by acylat...
|
|
WO/2007/074788 |
[PROBLEMS] To provide a pharmaceutical composition comprising a ceramide-related substance having little adverse side effects as an active ingredient by using a raw material that is highly safe to a human body and is inexpensive. [MEANS ...
|
|
WO/2007/070820 |
A method of preparing the anthracyclin carminomycin using a starting material comprising daunorubicin. The method comprises reacting daunorubicin or N-protected daunorubicin with soft Lewis acids for the demethylation of the 4-methoxy gr...
|
|
WO/2007/068578 |
The current invention relates to a continuous process for preparing heat an alkali stable polyol composition. Alkali is added to the feed of the anion exchange resin and is allowing running the resin battery in full service mode.
|
|
WO/2007/069733 |
[PROBLEMS] To provide a method for production of a ceramide-related substance from a biological tissue without the need of using an organic solvent such as ethanol which is absolutely necessary in a conventional extraction process and an...
|
|
WO/2007/068171 |
The present invention relates to a new crystalline form of 3,4',5-trihydroxy-stilbene-3-β-D-glucoside, its preparation method and the use, as well as a pharmaceutical composition containing the same. The form I of 3,4',5-trihydroxy-stil...
|
|
WO/2007/070820 |
A method of preparing the anthracyclin carminomycin using a starting material comprising daunorubicin. The method comprises reacting daunorubicin or N-protected daunorubicin with soft Lewis acids for the demethylation of the 4-methoxy gr...
|
|
WO/2007/068745 |
The invention concerns novel polyunsaturated compounds of formula (I) wherein: R1 represents a R'1, -A-R'1 group, R'1 being selected among - COOH, -COOR3, -CONH2, -CONHR3, -CONR3 R4, -CHO, -CH2OH, -CH2OR5, and A represents a C2-C16 alkyl...
|
|
WO/2007/066805 |
According to the invention, a compound represented by the formula (I) (wherein A represents an aryl group or a monocyclic or dicyclic heterocyclic group, R1 represents a halide, a nitro group, a substituted C1-6 alkyl group, an amino gro...
|
|
WO/2007/064954 |
The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.
|
|
WO/2007/064954 |
The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.
|
|
WO/2007/063356 |
The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds of this invention can be useful for inhibition and prevention of inflammation and associated pathologies, including inflammatory and a...
|
|
WO/2007/063356 |
The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds of this invention can be useful for inhibition and prevention of inflammation and associated pathologies, including inflammatory and a...
|
|
WO/2007/061796 |
The present invention relates generally to pharmaceutical compositions comprising non-caloric or low-caloric high-potency sweeteners and methods for making and using them, in particular, the present invention relates to different pharmac...
|
|
WO/2007/061796 |
The present invention relates generally to pharmaceutical compositions comprising non-caloric or low-caloric high-potency sweeteners and methods for making and using them, in particular, the present invention relates to different pharmac...
|
|
WO/2007/056525 |
The invention relates to high affinity Siglec ligands that are useful for isolating cells that express Siglecs and for delivering agents to cells that express Siglecs. In one embodiment, the invention provides a method for treating cance...
|
|
WO/2007/054977 |
The present invention relates to a compound of formula I: [(C)-(L')]n-(A)-[(L)-(B)]mwherein (A) is a thioglycosylated cysteine of formula IIa or IIb: IIa IIb; (B) is a melanogenosis-inhibiting peptide comprising peptide sequence selected...
|
|
WO/2007/049819 |
Disclosed is a therapeutic agent for a disease in which an NKT cell or the stimulation of an NKT cell is involved in the aggravation of a morbid condition thereof. The therapeutic agent comprises a chemically synthesized glycolipid deriv...
|
|
WO/2007/050668 |
There are disclosed compound of formula I, in which R1 represents a hydrophobic moiety adapted to occupy the C’ channel of human CDId, R2 represents a hydrophobic moiety adapted to occupy the A' channel of human CDId, such that R1 fill...
|
|
WO/2007/048974 |
The invention concerns novel glycoside oligomers, monomers useful for preparing same, as well as a method for preparing such oligomers and in particular D-glucosamine and N-acétyl-D-glucosamine heterooligomers, enabling the size, the de...
|
|
WO/2007/048974 |
The invention concerns novel glycoside oligomers, monomers useful for preparing same, as well as a method for preparing such oligomers and in particular D-glucosamine and N-acétyl-D-glucosamine heterooligomers, enabling the size, the de...
|
|
WO/2007/045469 |
The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new compounds useful as adjuvants for prophylactic and/or therapeutic vaccination...
|
|
WO/2007/042469 |
The present invention relates compounds of the formula: oligosaccharide-spacer-(GpIIb/IIIa antagonist), wherein the oligosaccharide is a negatively charged oligosaccharide residue comprising four to twenty five monosaccharide units, the ...
|
